Clinical significance of foscarnet sodium combined with cervical conization in treatment of cervical intraepithelial neoplasia with human papilloma virus infection

Abstract

Objective To explore the effect of antiviral drug foscarnet sodium on the negative rate and reinfection rate of human papillomavirus (HPV) after loop electrosurgical excision procedure (LEEP) treatment for cervical high-grade squamous intraepithelial lesion (HISL) patients. Methods Patients (n=137) of CIN Ⅱ-Ⅲ combined with high-risk HPV infection were selected from the Department of Gynecology of Liuzhou People’s Hospital from January 2016 to May 2017. They were randomly divided into control group (41 cases) and treatment group (96 cases) based on the ratio of 3∶7. The control group received LEEP only. The treatment group were treated with foscarnet sodium intravenous infusion of 3.0 g, once a day for 14 days after LEEP. The patients with positive margins accepted cold knife conization again, and the negative incisal edge was included in the research. HPV negative rate and reinfection rate were compared between two groups at the 3rd, 6th, 12th months after the treatment. Results Two cases (4.88%) were lost in the control group, 5 cases (5.21%) were lost in the treatment group. At the 3rd, 6th, 12th months after the treatment, HPV negative rates were significantly higher in treatment group [85.7% (78/91) , 91.2% (83/91) and 93.4% (85/91) ] than those in the control group [69.2% (27/39) , 71.8% (28/39) and 76.9% (30/39) ], and the differences had statistical significance (χ2=4.76, 8.25, 7.27, P all 0.05) . Conclusions Foscarnet sodium combined with LEEP in the treatment of high grade CIN with high risk HPV infection contributes to HPV negative conversion but cannot prevent reinfection of HPV. Key words: Cervical intraepithelial neoplasia; Forscarnet sodium; Negative rate; Reinfection